Interestingly, STAT3 activation seems to be a general mechanism of acquired resistance since it was also observed in cancer cells driven by diverse kinases, including EGFR, HER2, ALK, and MET, as well as mutant KRAS following treatment with specific inhibitors [47]. Here, ERBB2 is linked to cancer.